Knockdown of HMGB1 improves apoptosis and suppresses proliferation and invasion of glioma cells

Chinese Journal of Cancer Research

Volumn 26, Issue 6, 2014, Pages 658-668

  Zhang, Jing ^a   Liu, Cang ^a   Hou, Ruiguang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Glioma; High mobility group protein box 1 (HMGB1); Invasion; Proliferation; SiRNA

Indexed keywords

CYCLIN D1; GELATINASE B; HIGH MOBILITY GROUP B1 PROTEIN; PROTEIN BAX; PROTEIN BCL 2; RNA; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; GENE REPRESSION; GENE SILENCING; GENETIC TRANSFECTION; GLIOMA CELL; HUMAN; HUMAN CELL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84940037855     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.3978/j.issn.1000-9604.2014.12.05     Document Type: Article

References (56)

1. Rees JH. Diagnosis and treatment in neuro-oncology: an oncological perspective. Br J Radiol 2011;84 Spec No 2:S82-9.
2. Osman MA. Phase II trial of temozolomide and reirradiation using conformal 3D-radiotherapy in recurrent brain gliomas. Ann Transl Med 2014;2:44.
3. Al-Mulla F, Bitar MS, Al-Maghrebi M, et al. Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3β. Cancer Res 2011;71:1334-43.
4. Wang J, Ma Y, Cooper MK. Cancer stem cells in glioma: challenges and opportunities. Transl Cancer Res 2013;2:429-41.
5. Cai LB, Li J, Lai MY, et al. Bevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma. Chin J Cancer Res 2013;25:206-11.
6. Chen Y, Liu D. Chimeric antigen receptor (CAR)-directed adoptive immunotherapy: a new era in targeted cancer therapy. Stem Cell Investigation 2014;1:2.
7. Ngalame NN, Tokar EJ, Person RJ, et al. Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic. Toxicol Sci 2014;138:268-77.
8. Shrestha Y, Schafer EJ, Boehm JS, et al. PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. Oncogene 2012;31:3397-408.
9. Baskaran D, Spirin PV, Prasolov VS. Activated leukemic oncogenes responsible for neoplastic transformation of hematopoietic cells. Mol Biol (Mosk) 2010;44:418-30.
10. Boccaccio C, Comoglio PM. The MET oncogene in glioblastoma stem cells: implications as a diagnostic marker and a therapeutic target. Cancer Res 2013;73:3193-9.
11. Li J, Gupta S, Li C. Research perspectives: gold nanoparticles in cancer theranostics. Quant Imaging Med Surg 2013;3:284-91.
12. Feng H, Hu B, Vuori K, et al. EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180. Oncogene 2014;33:2504-12.
13. Ibrahim NY, Abdel Aal HH, Abdel Kader MS, et al. Reducing late effects of radiotherapy in average risk medulloblastoma. Chin Clin Oncol 2014;3:3.
14. Paul AG, Chandran B, Sharma-Walia N. Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies. Transl Res 2013;162:77-92.
15. McCubrey JA, Demidenko ZN. Recent discoveries in the cycling, growing and aging of the p53 field. Aging (Albany NY) 2012;4:887-93.
16. Gandarillas A. The mysterious human epidermal cell cycle, or an oncogene-induced differentiation checkpoint. Cell Cycle 2012;11:4507-16.
17. Süren D, Yıldırım M, Demirpençe Ö, et al. The role of high mobility group box 1 (HMGB1) in colorectal cancer. Med Sci Monit 2014;20:530-7.
18. Xiao J, Ding Y, Huang J, et al. The association of HMGB1 gene with the prognosis of HCC. PLoS One 2014;9:e89097.
19. Zhang J, Kou YB, Zhu JS, et al. Knockdown of HMGB1 inhibits growth and invasion of gastric cancer cells through the NF-kB pathway in vitro and in vivo. Int J Oncol 2014;44:1268-76.
20. Kang R, Zhang Q, Zeh HJ 3rd, et al. HMGB1 in cancer: good, bad, or both? Clin Cancer Res 2013;19:4046-57.
21. Riuzzi F, Sorci G, Donato R. RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth. Am J Pathol 2007;171:947-61.
22. Ditsworth D, Zong WX, Thompson CB. Activation of poly (ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus. J Biol Chem 2007;282:17845-54.
23. Zhang CL, Shu MG, Qi HW, et al. Inhibition of tumor angiogenesis by HMGB1 A box peptide. Med Hypotheses 2008;70:343-5.
24. Dong Xda E, Ito N, Lotze MT, et al. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother 2007;30:596-606.
25. Tang D, Kang R, Zeh HJ 3rd, et al. High-mobility group box 1 and cancer. Biochim Biophys Acta 2010;1799:131-40.
26. Bustin M. Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem Sci 2001;26:152-3.
27. Bonaldi T, Längst G, Strohner R, et al. The DNA chaperone HMGB1 facilitates ACF/CHRAC-dependent nucleosome sliding. EMBO J 2002;21:6865-73.
28. Mosevitsky MI, Novitskaya VA, Iogannsen MG, et al. Tissue specificity of nucleo-cytoplasmic distribution of HMG1 and HMG2 proteins and their probable functions. Eur J Biochem 1989;185:303-10.
29. Xu X, Zhu H, Wang T, et al. Exogenous high-mobility group box 1 inhibits apoptosis and promotes the proliferation of lewis cells via RAGE/TLR4-dependent signal pathways. Scand J Immunol 2014;79:386-94.
30. Gnanasekar M, Kalyanasundaram R, Zheng G, et al. HMGB1: A Promising Therapeutic Target for Prostate Cancer. Prostate Cancer 2013;2013:157103.
31. Carvajal IM, Baron RM, Perrella MA. High-mobility group-I/Y proteins: Potential role in the pathophysiology of critical illnesses. Crit Care Med 2002;30:S36-42.
32. Akaike H, Kono K, Sugai H, et al. Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer. Anticancer Res 2007;27:449-57.
33. Thomas JO, Travers AA. HMG1 and 2, and related 'architectural' DNA-binding proteins. Trends Biochem Sci 2001;26:167-74.
34. Völp K, Brezniceanu ML, Bösser S, et al. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 2006;55:234-42.
35. Ranganathan A, Gunnarsson O, Casarett D. Palliative care and advance care planning for patients with advanced malignancies. Ann Palliat Med 2014;3:144-9.
36. Lam S, Lin Y, Warnke PC. Permeability imaging in pediatric brain tumors. Transl Pediatr 2014;3:218-28.
37. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-9.
38. Moriwaka Y, Luo Y, Ohmori H, et al. HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer. Pathobiology 2010;77:17-23.
39. Fukami A, Adachi H, Yamagishi S, et al. Factors associated with serum high mobility group box 1 (HMGB1) levels in a general population. Metabolism 2009;58:1688-93.
40. Yang H, Tracey KJ. Targeting HMGB1 in inflammation. Biochim Biophys Acta 2010;1799:149-56.
41. Taguchi A, Blood DC, del Toro G, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405:354-60.
42. Chalmers SA, Eidelman AS, Ewer JC, et al. A role for HMGB1, HSP60 and Myd88 in growth of murine mammary carcinoma in vitro. Cell Immunol 2013;282:136-45.
43. Atadja P, Wong H, Veillete C, et al. Overexpression of cyclin D1 blocks proliferation of normal diploid fibroblasts. Exp Cell Res 1995;217:205-16.
44. Chen RC, Yi PP, Zhou RR, et al. The role of HMGB1-RAGE axis in migration and invasion of hepatocellular carcinoma cell lines. Mol Cell Biochem 2014;390:271-80.
45. Yin Y, Li W, Deng M, et al. Extracellular high mobility group box chromosomal protein 1 promotes drug resistance by increasing the expression of P-glycoprotein expression in gastric adenocarcinoma cells. Mol Med Rep 2014;9:1439-43.
46. Bald T, Quast T, Landsberg J, et al. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature 2014;507:109-13.
47. Fiuza C, Bustin M, Talwar S, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003;101:2652-60.
48. Treutiger CJ, Mullins GE, Johansson AS, et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 2003;254:375-85.
49. Gong W, Wang ZY, Chen GX, et al. Invasion potential of H22 hepatocarcinoma cells is increased by HMGB1-induced tumor NF-kB signaling via initiation of HSP70. Oncol Rep 2013;30:1249-56.
50. Das SK, Bhutia SK, Kegelman TP, et al. MDA-9/syntenin: a positive gatekeeper of melanoma metastasis. Front Biosci (Landmark Ed) 2012;17:1-15.
51. Chetty C, Vanamala SK, Gondi CS, et al. MMP-9 induces CD44 cleavage and CD44 mediated cell migration in glioblastoma xenograft cells. Cell Signal 2012;24:549-59.
52. Sen T, Chatterjee A. Epigallocatechin-3-gallate (EGCG) downregulates EGF-induced MMP-9 in breast cancer cells: involvement of integrin receptor α5β1 in the process. Eur J Nutr 2011;50:465-78.
53. Chen YY, Chiang SY, Lin JG, et al. Emodin, aloe-emodin and rhein inhibit migration and invasion in human tongue cancer SCC-4 cells through the inhibition of gene expression of matrix metalloproteinase-9. Int J Oncol 2010;36:1113-20.
54. Kim A, Kim MJ, Yang Y, et al. Suppression of NF-kappaB activity by NDRG2 expression attenuates the invasive potential of highly malignant tumor cells. Carcinogenesis 2009;30:927-36.
55. Kanno T, Kamba T, Yamasaki T, et al. JunB promotes cell invasion and angiogenesis in VHL-defective renal cell carcinoma. Oncogene 2012;31:3098-110.
56. Argast GM, Krueger JS, Thomson S, et al. Inducible expression of TGF, snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model. Clin Exp Metastasis 2011;28:593-614.